PT - JOURNAL ARTICLE AU - Moksnes, Marta R AU - Røsjø, Helge AU - Richmond, Anne AU - Lyngbakken, Magnus N AU - Graham, Sarah E AU - Hansen, Ailin Falkmo AU - Wolford, Brooke N AU - Taliun, Sarah A Gagliano AU - LeFaive, Jonathon AU - Rasheed, Humaira AU - Thomas, Laurent F AU - Zhou, Wei AU - Surakka, Ida AU - Douville, Nicholas J AU - Campbell, Archie AU - Porteous, David J AU - Welsh, Paul AU - Sattar, Naveed AU - Smith, George Davey AU - Fritsche, Lars G AU - Nielsen, Jonas B AU - Åsvold, Bjørn Olav AU - Hveem, Kristian AU - Hayward, Caroline AU - Willer, Cristen J AU - Brumpton, Ben M AU - Omland, Torbjørn TI - Using human genetics to understand the causes and consequences of circulating cardiac troponin I in the general population AID - 10.1101/2020.09.04.20187401 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.04.20187401 4099 - http://medrxiv.org/content/early/2020/09/05/2020.09.04.20187401.short 4100 - http://medrxiv.org/content/early/2020/09/05/2020.09.04.20187401.full AB - Circulating cardiac troponin proteins are associated with structural heart disease and predict incident cardiovascular disease in the general population. However, the genetic contribution to cardiac troponin I (cTnI) concentrations and its causal effect on cardiovascular phenotypes is unclear. We combine data from the Trøndelag Health Study and the Generation Scotland Scottish Family Health Study and perform a genome-wide association study of highsensitivity cTnI concentrations with 48 115 individuals.We identified 12 genetic loci (8 novel) associated with cTnI concentrations. Associated protein-altering variants highlighted putative functional genes: CAND2, HABP2, ANO5, APOH, FHOD3, TNFAIP2, KLKB1 and LMAN1. Using two-sample Mendelian randomization we confirmed the non-causal role of cTnI in acute myocardial infarction, but could not rule out a causal role for cTnI in heart failure. Using genetically informed methods for causal inference of cTnI helps inform the role and value of measuring cTnI in the general population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe genotyping in HUNT was financed by the National Institutes of Health, University of Michigan, the Research Council of Norway, the Liaison Committee for Education, Research and Innovation in Central Norway, and the Joint Research Committee between St Olav's hospital and the Faculty of Medicine and Health Sciences, NTNU.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study in HUNT has been approved by the Norwegian Data Protection Authority and the Regional Committee for Medical Health Research Ethics in Central Norway, and the study in GS:SFHS has been approved by The National Health Service Tayside Committee on Medical Research EthicsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated or analyzed during this study are available from the corresponding authors upon reasonable request.